Neural Mobilisation Effect on Calf Muscle

May 12, 2026 updated by: NITHIYAH MARUTHEY, INTI International University

The Effect of Neural Mobilization on Calf Muscle Length and Strength in Ballet Dancers: a Randomized Controlled Trial

The purpose of this study was to investigate Neural mobilisation effects on calf muscles length and strength is crucial to optimize ballet performance and prevent injuries.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

A randomized controlled trial is conducted with a total of 54 non-professional ballet dancers recruited from ballet studios across the Klang Valley following inclusion and exclusion criteria. Baseline measurement of calf muscle performance was conducted before randomization using knee-to-wall (KtW) test, handheld dynamometer (HHD) and Y-balance (YBT). Participants were allocated to experimental (NM and self-stretching) or control (self stretching) .

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
54

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Malaysia
    • Negeri Sembilan
      • Seremban, Negeri Sembilan, Malaysia, 71800
        • INTI International University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Classical ballet trained female or male .
  • Subjects who are trained in classical ballet syllabus such as Royal Academy of Dance (RAD) Syllabus, The Classical Ballet Syllabus by Commonwealth Society of Teachers of Dancing (CSTD), Vaganova Syllabus and more.
  • Aged 13-23 years old
  • Dancers who took class/practice ballet for at least 3 times per week
  • Participated in ballet competition in recent 6 months

Exclusion Criteria:

  • Professional full time ballet dancers
  • Non-ballet dancers
  • Self-reported lower extremity injuries in the past 6 months prior to date of data collection
  • Subjects with existing musculoskeletal injuries might affect calf muscle performance
  • Involvement in other sports or physical training

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Neural mobilisation group
neural mobilisation of tibial nerve and gastrocnemius stretching
Other: Neural mobilisation
the neural mobilisation was done with placement of participant's leg in hip flexion, knee extension, ankle dorsiflexion and eversion to load the nerve. Then leg is placed back to neutral position, with ankle naturally plantarflexed to unload the nerve. NM of tibial nerve was done in a total of 10 seconds each repetition, with 5 seconds each for loading and unloading of nerve. Then 12 repetition was done in one set, which amount to a total of 120seconds or 2 minute per set. A total of 3 sets was done on each leg, with a 1-minute resting interval after each set. NM was administered to participants in experimental group before their ballet class for 3 times a week lasting for 4 weeks.
Other Names:
  • nerve gliding
  • nerve tensioning
Other: Gastrocnemius stretching
Participants was instructed to perform the classic wall stretch for gastrocnemius as self-stretching for a duration of 30 seconds each leg. It was done facing the wall and one leg had knee flexed in front while the other leg had knee extended behind. A 30 second hold was maintained at maximum stretched position by leaning forward while both soles of feet remain contact on the ground. Self-stretch was performed throughout the 4-week study duration before every ballet training or class.
Other Names:
  • calf self stretching
Active Comparator: Gastrocnemius stretching group
Participants was instructed to perform the classic wall stretch for gastrocnemius as self-stretching for a duration of 30 seconds each leg. It was done facing the wall and one leg had knee flexed in front while the other leg had knee extended behind. A 30 second hold was maintained at maximum tretched position by leaning forward while both soles of feet remain contact on the round. Self-stretch was performed throughout the 4-week study duration before every ballet training or class.
Other: Gastrocnemius stretching
Participants was instructed to perform the classic wall stretch for gastrocnemius as self-stretching for a duration of 30 seconds each leg. It was done facing the wall and one leg had knee flexed in front while the other leg had knee extended behind. A 30 second hold was maintained at maximum stretched position by leaning forward while both soles of feet remain contact on the ground. Self-stretch was performed throughout the 4-week study duration before every ballet training or class.
Other Names:
  • calf self stretching

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
knee to wall test
Time Frame: From enrollment to the end of treatment at 4 weeks
The participants placed the testing foot onto the measuring tape with foot perpendicular to the wall while lunging or bending the knee to touch the wall. Then participants slide their foot further away from the wall as much as ossible while maintaining contact of knee to the wall as well as heel of foot on the floor. The calf muscle flexibility is evaluated with the measurement of distance from the great toe to the wall will be the maximum possible ankle dorsiflexion for the individual.
From enrollment to the end of treatment at 4 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Calf muscle strength
Time Frame: From enrollment to the end of treatment at 4 weeks
Calf muscle strength was measured using handheld dynamometer (HHD).The device was placed at the plantar aspect of metatarsophalangeal joint height and the body of HHD should be maintained perpendicular to the plane of ankle plantarflexion movement. Isometric contraction of ankle plantarflexor was done in maximum possible force for 5 seconds. Participant performed one trial to familiarize with the test, followed by 3 repetitions alternated on each leg with 1-minute resting interval.
From enrollment to the end of treatment at 4 weeks
Dynamic balance using Modified Star Excursion Balance Test (mSEBT)
Time Frame: From enrollment to the end of treatment at 4 weeks
Participants maintained their hands on the hip and reached tip of hallux to the maximal distance. The reaching foot were to avoid touching the ground and the heel of standing foot should remain on the ground. One trial on each direction was performed to familiarize with the test, followed by three trials with 1 minute resting interval. Normalize reach distance to lower limb length and normalized composite score were calculated to ultimately evaluate dynamic balance of an individual.
From enrollment to the end of treatment at 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
INTI International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: NITHIYAH MARUTHEY, INTI International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 20, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 15, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 6, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 13, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 14, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 12, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • INTI-IU/FHLS-RC/BPTHI/1NY12024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Upon careful consideration it will be decided to protect participants privacy

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings